Safety Reporting For Combo Products To Be Clarified In FDA Proposed Rule
A proposed rule wending its way through regulatory review at FDA would clarify post-market safety reporting requirements for combination products
You may also be interested in...
FDA is revisiting its Intercenter Agreements on combination product jurisdictions in light of its final rule defining primary mode of action
Solvay may need a more restrictive Risk Evaluation and Mitigation Strategy for AndroGel 1% to adequately warn against the danger of secondary transfer of the testosterone gel, according to some members of FDA's Pediatric Advisory Committee
Agency comes to same conclusion as advisory committee: the risky schizophrenia drug could get approved if an appropriate patient group is identified.